CBG and CBN: The Cannabinoids Nobody Explains Well
Aktie
CBG and CBN: The Cannabinoids Nobody Explains Well
In this guide
1. CBG: the cannabis "mother molecule"
"Mother molecule" or stem cell cannabinoid is a popularizing nickname — it doesn't appear that way in primary scientific literature — but the biochemical fact behind it is solidly proven.
CBGA (the acidic form of CBG, as it exists in the living plant) is the common precursor of the three major cannabinoid acids: THCA, CBDA, and CBCA. Fellermeier & Zenk (1998, FEBS Letters) identified the enzyme that produces CBGA from olivetolic acid and GPP; Gagné et al. (2012, PNAS) described the cyclase that makes that starting olivetolic acid. From there, three separate enzymes — THCA synthase, CBDA synthase, and CBCA synthase — convert that same CBGA into each "daughter" cannabinoid through oxidative cyclization (Taura et al. 2007, FEBS Letters). Luo et al. (2019, Nature) reconstructed this entire production pathway in genetically engineered yeast, confirming the complete mechanism.
This explains why CBG(A) predominates in the plant's early growth stages (Pacifico et al. 2008, Euphytica; Aizpurua-Olaizola et al. 2016, Journal of Natural Products) and why, in the mature flower, usually only a remnant is left: most of it has already been enzymatically converted into THCA, CBDA, or CBCA before harvest.
There are genetics specifically bred to accumulate CBG instead of converting it — known as "Type IV" varieties, and their genetic basis has been identified: they carry a non-functional version (null allele) of the THCA synthase gene, recessively inherited (Garfinkel, Otten & Crawford, 2021, Genes). Without that enzymatic conversion, CBG stays accumulated instead of transforming.
2. CBN: the plant doesn't make it, time does
This is the most important and least understood difference: unlike THC, CBD, or CBG, CBN has no dedicated enzyme that synthesizes it inside the plant. It forms afterward, outside the living plant, through chemical degradation.
CBN forms through non-enzymatic oxidation of THC exposed to oxygen, light, and heat over time (Holmes et al. 2021, Frontiers in Pharmacology). The exact chemical process — via oxidized intermediates that end up aromatizing one of the molecule's rings — was originally described in Turner & ElSohly (1979) and is still cited in current studies. With concrete data: Ross & ElSohly (UNODC Bulletin, 1997) documented that after 4 years at room temperature, the CBN/THC ratio in a sample can rise to nearly 14%. A more recent study on seized resin over 8 years (Farah et al. 2025, Scientific Reports) confirmed that same progressive degradation trend, and a Spanish lab (Ferreiro-Vera et al. 2022, Frontiers in Chemistry) showed that even the heat from a simple lab analysis speeds up the conversion.
The practical conclusion is the opposite of what most marketing suggests: a high CBN content in a cannabis sample is, above all, an indicator that the product is old or has degraded — not a trait someone deliberately cultivated for "more sedative potency."
3. What science says about CBG (and what it doesn't)
This is where we need to be stricter, because almost all available evidence on CBG is preclinical — meaning in isolated cells or in mice, not in people.
- Alpha-2 adrenergic receptors: Cascio et al. (2010, British Journal of Pharmacology) — an in vitro study — found CBG to be a very potent agonist of these receptors
- 5-HT1A receptor: the same Cascio et al. study shows CBG acting as an antagonist — also in vitro
- CB1/CB2: Navarro et al. (2018, Frontiers in Pharmacology) note that CBG behaves as a partial CB2 agonist, with low-to-moderate affinity — again, only in in vitro models
- TRPV1/TRPV2/TRPA1 receptors: De Petrocellis et al. (2011, British Journal of Pharmacology) — an in vitro study — show activation of these channels, linked to pain and temperature perception
The most-cited neuroprotection study (Valdeolivas et al. 2015, Neurotherapeutics) used an animal model (mice) of Huntington's disease — not people. Most follow-up studies on Huntington's or multiple sclerosis use synthetic CBG derivatives (like VCE-003), not pure CBG, an important distinction rarely clarified in popular articles. In gut inflammation, Borrelli et al. (2013, Biochemical Pharmacology) also worked with a preclinical mouse model of experimental colitis, plus in vitro assays.
In humans, available evidence is far more limited: a Phase 1 safety trial (Johns Hopkins team, doses up to 200mg) showed good tolerance with no major notable effects; a crossover trial on anxiety and mood published in 2024 in Scientific Reports found no marked changes; and there's an ongoing observational study (registry identifier NCT05743985). There is currently no human clinical trial of CBG for Huntington's disease — only in rodents.
4. The "potent sedative" CBN myth
It's probably the most repeated claim about CBN in "sleep aid" product marketing — and the one with the least solid scientific backing to date.
CBN does bind cannabinoid receptors, but with lower affinity than THC: at CB1, its binding constant (Ki) is about 211 nM versus THC's 21 nM —meaning roughly 10 times weaker— and at CB2 it's around 126 nM (Rhee et al. 1997, Journal of Medicinal Chemistry).
Corroon (2021, Cannabis and Cannabinoid Research) reviewed all available human evidence on CBN and concluded that, at that point, there were no trials with scientifically validated sleep measures backing the commercial claims. Russo (2011, British Journal of Pharmacology, a classic review on the "entourage effect") proposes an interesting alternative hypothesis: the sedative effect historically attributed to CBN could actually be due to myrcene (a terpene) present in the same aged samples that also have more CBN — a plausible hypothesis, but not directly and conclusively proven.
Since 2024, the first serious clinical trials have started to appear: one large one (over 1,000 participants), funded by the manufacturer of the studied product, found no difference versus melatonin (Kolobaric et al. 2024). A preclinical rat study with objective EEG measurement (Arnold et al. 2024, Neuropsychopharmacology) did show an effect comparable to zolpidem (a hypnotic drug) — but the authors themselves explicitly call for human confirmation before drawing conclusions. As of today, the claim that CBN is "a potent natural sedative" doesn't have the robust scientific backing that much of the marketing suggests.
5. Legal status in the EU and Spain
Unlike CBD —which has a relatively clear framework as an unauthorized "Novel Food" substance in the EU, but at least a defined one— CBG and CBN live in a much grayer zone.
There's no report dedicated specifically to CBG or CBN from the European Union Drugs Agency (EUDA, formerly EMCDDA) — they're only mentioned in passing, noting that "the regulatory framework is still developing." Neither the 1961 Single Convention nor Spanish regulations (AEMPS, National Drug Plan) name them specifically. The most concrete data available: a European Commission document (Standing Committee on Novel Food, February 2023) confirms that both CBG and CBN fall within the generic "cannabinoids" category of the Novel Food catalogue —not authorized as food— just like CBD. Three Novel Food authorization applications specific to CBG were closed without authorization in 2024.
Unlike CBD (non-psychoactive), CBN is chemically derived from THC and retains mild but real activity at the CB1 receptor —as documented above. This means equating it to CBD in legal or risk-perception terms isn't entirely accurate, and it's a real regulatory gap that no official source has explicitly resolved yet.
6. Can you already buy it in Europe?
Yes, real commercial supply exists: CBG-dominant flower (marketed as "White CBG" and similar variants) and sleep-oriented CBN products already circulate in specialty and online shops across several European countries. What doesn't exist is a specific, verifiable market figure for CBG or CBN separate from the general CBD market —neither the European hemp industry association (EIHA) nor any institutional report publishes that breakdown— so any "CBG market worth millions of euros" figure circulating should be treated with skepticism.
7. Frequently asked questions
In vitro evidence suggests low-to-moderate interaction with CB1/CB2 receptors, very different from THC. There are no human trials describing a significant psychoactive effect comparable to THC.
No. They're different molecules with different origins: the plant synthesizes CBD directly (via CBDA), while CBN forms through THC degradation over time. CBN retains mild activity at the CB1 receptor that CBD doesn't have.
There's no robust scientific evidence in humans confirming that yet. The largest trials published through 2024 showed no clear difference versus melatonin, and the hypothesis that the "sedative" effect actually comes from terpenes like myrcene present in old samples remains unproven conclusively.
Because in the plant it naturally converts into THC, CBD, or CBC before harvest. Only genetically specific varieties (with a mutation that blocks that conversion) accumulate CBG instead of transforming it, making them rarer and more costly to produce.
There's no Spanish regulation that mentions them specifically. At the EU level, both are classified under the unauthorized generic "cannabinoids" category of the Novel Food catalogue, same as CBD — but there isn't as developed or specific a framework as CBD's.
This article is for informational and educational purposes only, covering plant biochemistry and published scientific evidence. It does not constitute medical advice or replace consultation with a healthcare professional. Most studies cited on CBG and CBN are preclinical or small-sample — they should not be interpreted as proof of established clinical efficacy.
Grow knowledge, not just plants
Grinders, rolling papers, custom lighters, and accessories — everything around the experience, within the law.
See the Beetle Print catalogue